Literature DB >> 35721619

Perspective on Nonsteroidal Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease.

Jasleen K Ghuman1, Katherine R Tuttle1,2,3.   

Abstract

Entities:  

Keywords:  chronic kidney disease prevention; diabetes and the kidney; diabetic kidney disease; kidney health; nonsteroidal mineralocorticoid receptor antagonist

Mesh：

Substances：

Year:  2022        PMID： 35721619      PMCID： PMC9136905          DOI： 10.34067/KID.0007072021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  13 in total

1.  Effects of flow rate and potassium intake on distal tubular potassium transfer.

Authors:  R N Khuri; W N Strieder; G Giebisch
Journal:  Am J Physiol       Date:  1975-04

Review 2.  Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.

Authors:  Johann Bauersachs; Frédéric Jaisser; Robert Toto
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

3.  Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.

Authors:  Jana Grune; Niklas Beyhoff; Elia Smeir; Remigiusz Chudek; Annelie Blumrich; Zsofia Ban; Sarah Brix; Iris R Betz; Michael Schupp; Anna Foryst-Ludwig; Robert Klopfleisch; Philipp Stawowy; René Houtman; Peter Kolkhof; Ulrich Kintscher
Journal:  Hypertension       Date:  2018-02-05       Impact factor: 10.190

4.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

Authors:  Radica Z Alicic; Michele T Rooney; Katherine R Tuttle
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 8.237

5.  Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.

Authors:  Rajiv Agarwal; Amer Joseph; Stefan D Anker; Gerasimos Filippatos; Peter Rossing; Luis M Ruilope; Bertram Pitt; Peter Kolkhof; Charlie Scott; Robert Lawatscheck; Daniel J Wilson; George L Bakris
Journal:  J Am Soc Nephrol       Date:  2021-11-03       Impact factor: 10.121

6.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

7.  Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.

Authors:  Brendon L Neuen; Megumi Oshima; Vlado Perkovic; Rajiv Agarwal; Clare Arnott; George Bakris; Christopher P Cannon; David M Charytan; Robert Edwards; Jose L Górriz; Meg J Jardine; Adeera Levin; Bruce Neal; Luca De Nicola; Carol Pollock; Norman Rosenthal; David C Wheeler; Kenneth W Mahaffey; Hiddo J L Heerspink
Journal:  Eur Heart J       Date:  2021-12-21       Impact factor: 29.983

8.  Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

Authors:  Rajiv Agarwal; Gerasimos Filippatos; Bertram Pitt; Stefan D Anker; Peter Rossing; Amer Joseph; Peter Kolkhof; Christina Nowack; Martin Gebel; Luis M Ruilope; George L Bakris
Journal:  Eur Heart J       Date:  2022-02-10       Impact factor: 35.855

9.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.

Authors:  Bertram Pitt; Lars Kober; Piotr Ponikowski; Mihai Gheorghiade; Gerasimos Filippatos; Henry Krum; Christina Nowack; Peter Kolkhof; So-Young Kim; Faiez Zannad
Journal:  Eur Heart J       Date:  2013-05-27       Impact factor: 29.983

10.  Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.

Authors:  Rajiv Agarwal; Peter Kolkhof; George Bakris; Johann Bauersachs; Hermann Haller; Takashi Wada; Faiez Zannad
Journal:  Eur Heart J       Date:  2021-01-07       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.